Formulation and Characterization of Acetazolamide In Situ Cubogel
Overview
Glaucoma is a chronic eye disorder characterized by elevated intraocular pressure, which can lead to optic nerve damage and irreversible vision loss if untreated. Acetazolamide, a carbonic anhydrase inhibitor, effectively reduces aqueous humor production, but conventional ocular formulations are limited by poor bioavailability, rapid precorneal clearance, and the need for frequent dosing. To address these challenges, an acetazolamide-loaded in-situ cubogel was developed to provide sustained, targeted, and patient-friendly ocular delivery.Cubosomes were prepared using the top-down technique and optimized through a Box-Behnken Design. The optimized cubosome formulation contained 6.2% w/v Glyceryl monooleate, 0.35% w/v Pluronic F127 and 6.8 minutes sonication time, resulting in particle size of 256.7 nm, PDI of 0.473, zetapotential of 7.53 mV and entrapment efficiency of 80.35 %. Cryo-TEM confirmed the presence of well-ordered cubic nanostructures, and the dispersion was homogeneous, smooth, milky white and physically stable under storage conditions.In conclusion, the study successfully developed a stable, effective and patient-friendly acetazolamide in-situ cubogel.
This item is Non-Returnable
Customers Also Bought
Details
- ISBN-13: 9786630466096
- ISBN-10: 6630466098
- Publisher: LAP Lambert Academic Publishing
- Publish Date: September 2026
- Dimensions: 9 x 6 x 0.23 inches
- Shipping Weight: 0.31 pounds
- Page Count: 96
Related Categories
